KSR2
Summary:
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| kinase suppressor of ras 2 | MIM:610737 | Ensembl:ENSG00000171435 | HGNC:HGNC:18610 | PA134914125 | 12q24.22-q24.23 |
GO terms in KSR2
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IEA | GO:0004674 | protein serine/threonine kinase activity |
| MF | IPI | GO:0005515 | protein binding |
| MF | IEA | GO:0005524 | ATP binding |
| MF | IEA | GO:0046872 | metal ion binding |
| CC | IBA | GO:0005829 | cytosol |
| CC | IBA | GO:0005886 | plasma membrane |
| BP | IBA | GO:0007265 | Ras protein signal transduction |
| BP | IBA | GO:0019722 | calcium-mediated signaling |
Gene expression in normal tissue: KSR2
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in KSR2
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| wikipathways | WP231 | TNF alpha Signaling Pathway |
| wikipathways | WP4223 | Ras Signaling |
| kegg | hsa04014 | Ras signaling pathway - Homo sapiens (human) |
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-1643685 | Disease |
| reactome | R-HSA-5663202 | Diseases of signal transduction |
| reactome | R-HSA-5673001 | RAF/MAP kinase cascade |
| reactome | R-HSA-5674135 | MAP2K and MAPK activation |
| reactome | R-HSA-5683057 | MAPK family signaling cascades |
| reactome | R-HSA-5684996 | MAPK1/MAPK3 signaling |
| reactome | R-HSA-6802946 | Signaling by moderate kinase activity BRAF mutants |
| reactome | R-HSA-6802948 | Signaling by high-kinase activity BRAF mutants |
| reactome | R-HSA-6802949 | Signaling by RAS mutants |
| reactome | R-HSA-6802952 | Signaling by BRAF and RAF fusions |
| reactome | R-HSA-6802955 | Paradoxical activation of RAF signaling by kinase inactive BRAF |
| reactome | R-HSA-6802957 | Oncogenic MAPK signaling |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD307 | Manumycin A | 2 |
| iGMDRD512 | nutlin 3 | 2 |
| iGMDRD584 | VER 155008 | 2 |
| iGMDRD560 | MK-2206 | 2 |
| iGMDRD116 | CD437 | 3 |
| iGMDRD150 | RITA | 4 |
| iGMDRD79 | Gemcitabine | 1 |
| iGMDRD701 | NVP-AUY922 | 2 |
| iGMDRD523 | Cyanoquinoline, 11 | 2 |
| iGMDRD219 | Bax channel blocker | 3 |
| iGMDRD435 | BI-2536 | 2 |
| iGMDRD289 | Parthenolide | 2 |
| iGMDRD267 | Oligomycin A | 3 |
| iGMDRD872 | BRD7137 | 2 |
| iGMDRD871 | BRD6368 | 9 |
| iGMDRD286 | Nsc 632839 | 2 |
| iGMDRD300 | Tozasertib | 3 |
| iGMDRD505 | Pevonedistat | 6 |
| iGMDRD886 | Compound 1541A | 3 |
| iGMDRD353 | PD0325901 | 1 |
| iGMDRD126 | Tipifarnib | 6 |
| iGMDRD420 | Leucascandrolide A | 2 |
| iGMDRD772 | BRD4770 | 4 |
| iGMDRD889 | Compound 7d-cis | 1 |
| iGMDRD546 | BMS-754807 | 1 |
| iGMDRD781 | Sirolimus | 11 |
| iGMDRD446 | LY 2183240 | 2 |
| iGMDRD193 | Fqi1 | 1 |
| iGMDRD639 | YK 4-279 | 2 |
| iGMDRD280 | CYTOCHALASIN B | 2 |
| iGMDRD297 | Austocystin D | 9 |
| iGMDRD474 | Avrainvillamide | 2 |
| iGMDRD270 | Ciclosporin | 5 |
| iGMDRD309 | 17AAG | 1 |
| iGMDRD187 | BRD9876 | 2 |
| iGMDRD870 | BRD63610 | 2 |
| iGMDRD318 | PAC-1 | 4 |
| iGMDRD441 | TW 37 | 2 |
| iGMDRD399 | Selumetinib | 1 |
| iGMDRD887 | Compound 23 citrate | 3 |
| iGMDRD562 | Navitoclax | 4 |
| iGMDRD780 | PP-30 | 2 |
| iGMDRD506 | Fedratinib | 3 |
| iGMDRD577 | BIX01294 | 4 |
| iGMDRD369 | TGX-115 | 3 |
| iGMDRD874 | BRD8958 | 1 |
| iGMDRD268 | Cerulenin | 3 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in KSR2
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.